COMP <GO>
NPCE vs MRK // GROSS PROFIT MARGIN
Neuropace Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NPCE 2
— MRK 9
▲ GROSS PROFIT MARGIN LEADER: NPCE
LAST: $13.01 (+0.62%) • MKT CAP: $446.6M
gross-margins
77.20%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NPCE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NPCE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 77.20% | 74.80% | +2.40 | NPCE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -23.00% | 20.70% | -43.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.54% | 3.42% | -5.96 | MRK | /fcf-yield <GO> |
| Operating Margin | -16.30% | 34.30% | -50.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 28.10% | -49.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 25.10% | 1.30% | +23.80 | NPCE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.3 | 51.7 | -12.41 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $446.6M | $361.02B | -$360.57B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NPCE REV | MRK REV | NPCE GROSS % | MRK GROSS % | NPCE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $100.0M | $65.01B | 77.2% | 74.8% | -$11.3M | $12.36B |
| FY 2024 | $79.9M | $64.17B | 73.9% | 76.3% | -$18.3M | $18.10B |
| FY 2023 | $65.4M | $60.12B | — | — | -$19.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NPCE // BETA —
MRK // BETA 0.92